**FOI Ref: 6579**

**Category(ies): Clinical - Service Activity**

**Subject: Myelofibrosis Treatment**

**Date Received: 24/08/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?
 | Yes |
| 1. A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).
 | 5 patients with episodes in the last 6 months coded with the D47.4 ICD10 code |
| 1. B) How many of these patients were above age 65?
 | 5 |
| 1. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?
 | 1 |
| 1. A) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
 | 14 patients with episodes in the last 3 years coded with the D47.4 ICD10 code. |
| 1. B) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:
* Hydroxyurea
* Fedratinib
* Received No Treatment
 | Hydroxyurea - 1Fedratinib - NilReceived No Treatment – 9 without episodes in last 6 months |
| 1. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.
 | No TRFT (The Rotherham NHS Foundation Trust) does not participate in clinical trials for the treatment of myelofibrosis. |